Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th:
Karyopharm Therapeutics Inc. (KPTI - Free Report) : This pharmaceutical company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.8% over the last 60 days.
Karyopharm Therapeutics Inc. Price and Consensus
Karyopharm's shares gained 16% over the last one month compared to S&P 500’s rise of 14.8%. The company possesses a Momentum Score of A.
Karyopharm Therapeutics Inc. Price
Compugen Ltd. (CGEN - Free Report) : This therapeutic discovery company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.2% over the last 60 days.
Compugen Ltd. Price and Consensus
Compugen’s shares gained more than 100% over the last one month. The company possesses a Momentum Score of A.
Compugen Ltd. Price
AngloGold Ashanti Limited (AU - Free Report) : This gold mining company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.3% over the last 60 days.
AngloGold Ashanti Limited Price and Consensus
AngloGold’s shares gained 40.8% over the last one month. The company possesses a Momentum Score of A.
AngloGold Ashanti Limited Price
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th:
Karyopharm Therapeutics Inc. (KPTI - Free Report) : This pharmaceutical company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.8% over the last 60 days.
Karyopharm Therapeutics Inc. Price and Consensus
Karyopharm's shares gained 16% over the last one month compared to S&P 500’s rise of 14.8%. The company possesses a Momentum Score of A.
Karyopharm Therapeutics Inc. Price
Compugen Ltd. (CGEN - Free Report) : This therapeutic discovery company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.2% over the last 60 days.
Compugen Ltd. Price and Consensus
Compugen’s shares gained more than 100% over the last one month. The company possesses a Momentum Score of A.
Compugen Ltd. Price
AngloGold Ashanti Limited (AU - Free Report) : This gold mining company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.3% over the last 60 days.
AngloGold Ashanti Limited Price and Consensus
AngloGold’s shares gained 40.8% over the last one month. The company possesses a Momentum Score of A.
AngloGold Ashanti Limited Price
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AU - FREE
Get the latest research report on CGEN - FREE
Get the latest research report on KPTI - FREE